PD-L1 Antibody (MIH5) - BSA Free
Novus Biologicals | Catalog # NBP1-43262
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Format
Product Specifications
Immunogen
Clonality
Host
Isotype
Scientific Data Images for PD-L1 Antibody (MIH5) - BSA Free
Flow Cytometry: PD-L1 Antibody (MIH5) - BSA Free [NBP1-43262]
Flow Cytometry: PD-L1/B7-H1 Antibody (MIH5) [NBP1-43262] - B7-H1/PD-L1/CD274 Antibody (MIH5) [NBP1-43262] - Using the Allophycocyanin direct conjugate A cell surface stain was performed on RAW246.7 cells with B7-H1/PD-L1/CD274 (MIH5) antibody NBP1-43262APC (blue) and a matched isotype control NBP1-51104APC (orange). Cells were incubated in an antibody dilution of 0.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Allophycocyanin.Flow Cytometry: PD-L1 Antibody (MIH5) - BSA Free [NBP1-43262]
Flow Cytometry: PD-L1/B7-H1 Antibody (MIH5) [NBP1-43262] - B7-H1/PD-L1/CD274 Antibody (MIH5) [NBP1-43262] - Analysis using the Biotin conjugate of NBP1-43262. Staining of C57Bl/6 splenocytes with 0.125 ug of Rat IgG2a Isotype Control Biotin (open histogram) or 0.125 ug of Anti-Mouse (B7-H1) Biotin (filled histogram) followed by Streptavidin PE.Flow Cytometry: PD-L1 Antibody (MIH5) - BSA Free [NBP1-43262]
Flow Cytometry: PD-L1/B7-H1 Antibody (MIH5) [NBP1-43262] - B7-H1/PD-L1/CD274 Antibody (MIH5) [NBP1-43262] - Staining of mouse splenocytes with Anti-Mouse B7-H1/PD-L1/CD274) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.Flow Cytometry: PD-L1 Antibody (MIH5) - BSA Free [NBP1-43262]
Flow Cytometry: PD-L1/B7-H1 Antibody (MIH5) [NBP1-43262] - Analysis using the DyLight 488 conjugate of NBP1-43262. Staining of PD-L1 in human primary colon cancer cell using anti-PD-L1 antibody. Image from verified customer review.Flow Cytometry: PD-L1 Antibody (MIH5) - BSA Free [NBP1-43262]
Flow Cytometry: PD-L1/B7-H1 Antibody (MIH5) [NBP1-43262] - Analysis using the DyLight 488 conjugate of NBP1-43262. Staining of PD-L1 in HT29 cells using anti-PD-L1 antibody. The data shows the detection of total PD-L1 status in the cancer cells. Image from verified customer review.Applications for PD-L1 Antibody (MIH5) - BSA Free
Flow Cytometry
Immunohistochemistry
Immunohistochemistry-Frozen
Western Blot
Reviewed Applications
Read 1 review rated 4 using NBP1-43262 in the following applications:
Flow Cytometry Panel Builder
Bio-Techne Knows Flow Cytometry
Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.
Advanced Features
- Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
- Spillover Popups - Visualize the spectra of individual fluorochromes
- Antigen Density Selector - Match fluorochrome brightness with antigen density
Formulation, Preparation, and Storage
Purification
Formulation
Format
Preservative
Concentration
Shipping
Stability & Storage
Background: PD-L1/B7-H1
PD-L1 binding with receptor PD-1 results in phosphorylation of in the inhibitory tyrosine-based switch motif (ITSM) domain of PD-1, which leads to recruitment of Src homology 2 domain-containing protein tyrosine-phosphatase 2 (SHP-2) and eventual downstream phosphorylation of spleen tyrosine kinase (Syk) and phospholipid inositol-3-kinase (PI3K) (1,3). Under normal conditions, the PD-L1/PD-1 signaling axis helps maintain immune tolerance and prevent destructive immune responses by inhibiting T cell activity such as proliferation, survival, cytokine production, and cytotoxic T lymphocyte (CTL) cytotoxicity (1-3). In the tumor microenvironment (TME), however, the PD-L1/PD-1 signaling axis is hijacked to promote tumor cell survival and limit anti-tumor immune response (1,3). More precisely, tumor cells can escape killing and immune surveillance due to T cell exhaustion and apoptosis (1-3).
Given the role the PD-L1/PD-1 signaling axis plays in tumor cells' ability to evade immune surveillance, it has become a target of several immunotherapeutic agents in recent years (3,5). Antibody immunotherapies that target these inhibitory checkpoint molecules has shown great promise for cancer treatment (3,5). PD-L1 and PD-1 blocking agents have been approved for treatment in a number of cancers including melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, and Merkel-cell carcinoma (3,5). In many cancers the expression of PD-L1 in the TME has predictive value for response to blocking agents (3). Pembrolizumab, for example, is a PD-1 inhibitor that has been approved by the FDA as a second-line therapy for treatment of metastatic NSCLC in patients whose tumors express PD-L1 with a Tumor Proportion Score (TPS) greater than 1%, but also for first-line treatment in cases where patients' tumors expression PD-L1 with a TPS greater than 50%) (5). The most promising cancer immunotherapy treatments seem to point to combination therapy with both anti-cancer drugs (e.g. Gefitibin, Metformin, Etoposide) with PD-L1/PD-1 antibody blockade inhibitors (e.g. Atezolizumab, Nivolumab) (6).
References
1. Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: current researches in cancer. American journal of cancer research, 10(3), 727-742.
2. Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019). PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human vaccines & immunotherapeutics, 15(5), 1111-1122. https://doi.org/10.1080/21645515.2019.1571892
3. Sun, C., Mezzadra, R., & Schumacher, T. N. (2018). Regulation and Function of the PD-L1 Checkpoint. Immunity, 48(3), 434-452. https://doi.org/10.1016/j.immuni.2018.03.014
4. Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L., & Hung, M. C. (2019). Mechanisms Controlling PD-L1 Expression in Cancer. Molecular cell, 76(3), 359-370. https://doi.org/10.1016/j.molcel.2019.09.030
5. Tsoukalas, N., Kiakou, M., Tsapakidis, K., Tolia, M., Aravantinou-Fatorou, E., Baxevanos, P., Kyrgias, G., & Theocharis, S. (2019). PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(3), 883-888.
6. Gou, Q., Dong, C., Xu, H., Khan, B., Jin, J., Liu, Q., Shi, J., & Hou, Y. (2020). PD-L1 degradation pathway and immunotherapy for cancer. Cell death & disease, 11(11), 955. https://doi.org/10.1038/s41419-020-03140-2
Long Name
Alternate Names
Gene Symbol
Additional PD-L1/B7-H1 Products
Product Documents for PD-L1 Antibody (MIH5) - BSA Free
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Product Specific Notices for PD-L1 Antibody (MIH5) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Citations for PD-L1 Antibody (MIH5) - BSA Free
Customer Reviews for PD-L1 Antibody (MIH5) - BSA Free (1)
Have you used PD-L1 Antibody (MIH5) - BSA Free?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
-
Application: ImmunocytochemistrySample Tested: Blood mononuclear cells (PBMCs)Species: HumanVerified Customer | Posted 06/21/2017
There are no reviews that match your criteria.
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- 7-Amino Actinomycin D (7-AAD) Cell Viability Flow Cytometry Protocol
- Antigen Retrieval Protocol (PIER)
- Antigen Retrieval for Frozen Sections Protocol
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- Chromogenic IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Chromogenic Immunohistochemistry Staining of Frozen Tissue
- ClariTSA™ Fluorophore Kits
- Detection & Visualization of Antibody Binding
- Extracellular Membrane Flow Cytometry Protocol
- Flow Cytometry Protocol for Cell Surface Markers
- Flow Cytometry Protocol for Staining Membrane Associated Proteins
- Flow Cytometry Staining Protocols
- Flow Cytometry Troubleshooting Guide
- Fluorescent IHC Staining of Frozen Tissue Protocol
- Graphic Protocol for Heat-induced Epitope Retrieval
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Graphic Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- ICC Cell Smear Protocol for Suspension Cells
- ICC Immunocytochemistry Protocol Videos
- ICC for Adherent Cells
- IHC Sample Preparation (Frozen sections vs Paraffin)
- Immunocytochemistry (ICC) Protocol
- Immunocytochemistry Troubleshooting
- Immunofluorescence of Organoids Embedded in Cultrex Basement Membrane Extract
- Immunofluorescent IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Immunohistochemistry Frozen Troubleshooting
- Immunohistochemistry Paraffin Troubleshooting
- Intracellular Flow Cytometry Protocol Using Alcohol (Methanol)
- Intracellular Flow Cytometry Protocol Using Detergents
- Intracellular Nuclear Staining Flow Cytometry Protocol Using Detergents
- Intracellular Staining Flow Cytometry Protocol Using Alcohol Permeabilization
- Intracellular Staining Flow Cytometry Protocol Using Detergents to Permeabilize Cells
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Propidium Iodide Cell Viability Flow Cytometry Protocol
- Protocol for Heat-Induced Epitope Retrieval (HIER)
- Protocol for Liperfluo
- Protocol for Making a 4% Formaldehyde Solution in PBS
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Characterization of Human Th22 Cells
- Protocol for the Characterization of Human Th9 Cells
- Protocol for the Fluorescent ICC Staining of Cell Smears - Graphic
- Protocol for the Fluorescent ICC Staining of Cultured Cells on Coverslips - Graphic
- Protocol for the Preparation & Fixation of Cells on Coverslips
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections - Graphic
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections - Graphic
- Protocol for the Preparation and Fluorescent ICC Staining of Cells on Coverslips
- Protocol for the Preparation and Fluorescent ICC Staining of Non-adherent Cells
- Protocol for the Preparation and Fluorescent ICC Staining of Stem Cells on Coverslips
- Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- Protocol for the Preparation of a Cell Smear for Non-adherent Cell ICC - Graphic
- Protocol: Annexin V and PI Staining by Flow Cytometry
- Protocol: Annexin V and PI Staining for Apoptosis by Flow Cytometry
- R&D Systems Quality Control Western Blot Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: Fluorokine Flow Cytometry Kits
- Troubleshooting Guide: Immunohistochemistry
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars
FAQs for PD-L1 Antibody (MIH5) - BSA Free
-
Q: Can you recommend a mouse tissue positive control for this antibody hen used in IHC labelling?
A: CD274 in mouse is highly expressed in the heart, thymus, skeletal muscle, and lung. Weakly expressed in the kidney, spleen, thyroid, and liver. Expressed on activated dendritic cells, B-cells and macrophages. Expressed in numerous tumor cells lines of lymphoid origin. (UniProt Q9EP73) I would recommend trying heart, thymus, skeletal muscle, or lung for IHC. Here is a publication that used this clone with IHC staining of mouse tissues for your reference as well: Tsushima et al. Eur J Immunol. 2003 Oct;33(10):2773-82
-
Q: On your website, it states that clone MIH5 binds to both human and mouse CD274. However, other companies state this clone only binds to mouse. What type of validation do you have that this binds to human CD274?
A:
This antibody was tested on human primary colon cells and the cancer cells including HT29 cell line by one of our customer, and you can see the related data on the datasheet of this product. Datasheet
-
Q: Can you recommend a mouse tissue positive control for this antibody hen used in IHC labelling?
A: CD274 in mouse is highly expressed in the heart, thymus, skeletal muscle, and lung. Weakly expressed in the kidney, spleen, thyroid, and liver. Expressed on activated dendritic cells, B-cells and macrophages. Expressed in numerous tumor cells lines of lymphoid origin. (UniProt Q9EP73) I would recommend trying heart, thymus, skeletal muscle, or lung for IHC. Here is a publication that used this clone with IHC staining of mouse tissues for your reference as well: Tsushima et al. Eur J Immunol. 2003 Oct;33(10):2773-82
-
Q: On your website, it states that clone MIH5 binds to both human and mouse CD274. However, other companies state this clone only binds to mouse. What type of validation do you have that this binds to human CD274?
A:
This antibody was tested on human primary colon cells and the cancer cells including HT29 cell line by one of our customer, and you can see the related data on the datasheet of this product. Datasheet